Article Text

A7.06 Low-dose IL-2 therapy in refractory sle: Insights from a phase I/IIA clinical trial
  1. JY Humrich1,3,4,
  2. C von Spee-Mayer1,
  3. E Siegert1,
  4. M Bertolo1,
  5. D Abdirama1,
  6. A Rose1,
  7. P Enghard2,
  8. A Radbruch3,
  9. GR Burmester1,
  10. G Riemekasten4
  1. 1Department of Rheumatology and Clinical Immunology, Charité – University Medicine Berlin, Charitéplatz 1, 10117 Berlin, Germany
  2. 2Department of Nephrology and Intensive Care Medicine, Charité – University Medicine Berlin, Augustenburger Platz 1, 13353 Berlin, Germany
  3. 3German Rheumatism Research Center (DRFZ), a Leibniz Institute, Charitéplatz 1, 10117 Berlin, Germany
  4. 4Department of Rheumatology, University Hospital Schleswig-Holstein - Campus Lübeck, Ratzeburger Allee 160, 23538 Lübeck, Germany


Interleukin-2 (IL-2) is crucial for the growth and survival of regulatory T cells (Treg), and thus for the control of autoimmunity. In previous studies we have proven the significance of an acquired IL-2 deficiency and related Treg defects in the pathogenesis of systemic lupus erythematosus (SLE). Accordingly, we showed that compensation of IL-2 deficiency by IL-2 therapy corrects associated Treg defects and ameliorates already established disease in lupus-prone mice.1 Proceeding to a clinical translation of IL-2 therapy for SLE, we recently reported a rapid and robust reduction of disease activity in parallel to a remarkable expansion of the Treg population by low-dose IL-2 therapy in one patient with refractory SLE.2 In addition, we showed that Treg defects in SLE patients are associated with IL-2 deficiency, and can be selectively corrected in vitro and in vivo with low doses of IL-2.3 Together, these studies provided the rationales for the clinical implementation an IL-2-based immunotherapy for the treatment of SLE with the aim to restore Treg activity and thus to re-establish endogenous mechanisms of immune tolerance.

Here, we present results from the ongoing phase I/IIa clinical trial (PRO-IMMUN) addressing the safety, tolerability, immunological responses and clinical efficacy of a subcutaneous low-dose IL-2 therapy in patients with refractory SLE.


  1. Humrich JY, et al. Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus. Proc Natl Acad Sci USA. 2007;107(1):204–209

  2. Humrich JY, et al. Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE. Ann Rheum Dis. 2015. doi: 10.1136/annrheumdis-2014-206506

  3. von Spee-Mayer C, et al. Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus. Ann Rheum Dis. Aug 31 2015. doi: 10.1136/annrheumdis-2015-207776. [Epub ahead of print]

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.